Document Detail


Trandolapril restores circadian blood pressure variation in normoalbuminuric normotensive Type 1 diabetic patients.
MedLine Citation:
PMID:  11274903     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A large proportion, from 30% to 50%, of diabetic patients frequently manifests loss of the normal diurnal variation of blood pressure, i.e. their blood pressure does not show at least 10% fall at night (non-dippers). It has been demonstrated that non-dippers are at increased risk of end-organ damage, in particular, renal and cardiovascular complications. As no reliable means of reversing impaired blood pressure variation has been established so far, we aimed at assessing the effect of a long-acting angiotensin-converting enzyme (ACE) inhibitor trandolapril on the disturbed circadian blood pressure rhythm in diabetics without hypertension or nephropathy. A total of 18 type 1 diabetes patients (8 male, 10 female), aged 33.5+/-4.8, with duration of diabetes 5.8+/-2.8 years and HbA(1c) 6.6+/-0.4% (range 5.8--7.1%) were enrolled into the study. Ten well-matched type 1 diabetes patients served as an untreated control group. Twenty-four-hour ambulatory blood pressure measurements (ABPM) were performed thrice in each subject: before trandolapril, 2 mg once daily in the morning, was started; after the first dose of the drug; and after 2 weeks of the treatment. Mean (+/-S.D.) values of systolic, diastolic blood pressure, night fall in systolic, and diastolic blood pressure in the treatment group were (1) at baseline: 124.0+/-5.8 mm Hg, 89.3+/-4.2 mm Hg, 3.0+/-2.2%, 5.1+/-3.8%; (2) after the first dose: 116.1+/-7.6 mm Hg (P<.01 vs. baseline), 82.6+/-6.7 mm Hg (P<.01 vs. baseline), 4.2+/-2.6%, 4.7+/-2.5%; and (3) after 14-day treatment: 116.6+/-8.1 mm Hg (P<.01 vs. baseline), 76.9+/-9.6 mm Hg (P<.01 vs. baseline), 17.6+/-6.9% (P<.01 vs. baseline and after 24-h values), 19.4+/-8.0% (P<.01 vs. baseline and after 24-h values), respectively. ABPM results for the untreated controls were similar in all three measurements. In conclusion, within 14 days of trandolapril treatment, circadian blood pressure variation was successfully restored in normoalbuminuric normotensive insulin-dependent diabetic patients.
Authors:
L Czupryniak; M Wiśniewska-Jaronsińska; J Drzewoski
Related Documents :
2643413 - Hydrochlorothiazide is not additive to verapamil in treating essential hypertension.
23505703 - Use of butorphanol during immobilization of free-ranging white rhinoceros (ceratotheriu...
11369823 - The role of nitric oxide in hypertension and renal disease progression.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of diabetes and its complications     Volume:  15     ISSN:  1056-8727     ISO Abbreviation:  J. Diabetes Complicat.     Publication Date:    2001 Mar-Apr
Date Detail:
Created Date:  2001-03-29     Completed Date:  2001-06-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9204583     Medline TA:  J Diabetes Complications     Country:  United States    
Other Details:
Languages:  eng     Pagination:  75-9     Citation Subset:  IM    
Affiliation:
Metabolic Diseases and Gastroenterology Department, Medical University of Lodz, Ul. Kopcinskiego 22, 90-153 Lodz, Poland. czupryniak@yahoo.co.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Albuminuria
Antihypertensive Agents / therapeutic use*
Blood Pressure / drug effects*
Blood Pressure Monitoring, Ambulatory
Circadian Rhythm*
Diabetes Mellitus, Type 1 / drug therapy,  physiopathology*
Diastole / drug effects
Female
Humans
Indoles / therapeutic use*
Male
Systole / drug effects
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Indoles; 87679-37-6/trandolapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome: pilot study in elderl...
Next Document:  The control of blood glucose in the critical diabetic patient: a neuro-fuzzy method.